Published in Blood on March 26, 2015
ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease. Sci Transl Med (2015) 1.10
Interleukin-33 in health and disease. Nat Rev Immunol (2016) 0.92
Identification and validation of biomarkers associated with acute and chronic graft versus host disease. Bone Marrow Transplant (2015) 0.91
The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS (2016) 0.89
The Dynamic Role of the IL-33/ST2 Axis in Chronic Viral-infections: Alarming and Adjuvanting the Immune Response. EBioMedicine (2016) 0.88
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood (2016) 0.87
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood (2016) 0.84
Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol (2016) 0.83
Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol (2016) 0.83
Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis. Oncogene (2016) 0.80
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget (2016) 0.78
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight (2017) 0.78
Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight (2016) 0.78
Metabolic Complications Precede Alloreactivity and are Characterized by Changes in ST2 Signaling. Biol Blood Marrow Transplant (2016) 0.77
Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Biol Blood Marrow Transplant (2016) 0.77
Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction. Biol Blood Marrow Transplant (2016) 0.76
Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood (2016) 0.75
Controlling the burn and fueling the fire: defining the role for the alarmin interleukin-33 in alloimmunity. Curr Opin Organ Transplant (2016) 0.75
Emerging Roles of IL-33/ST2 Axis in Renal Diseases. Int J Mol Sci (2017) 0.75
Alarmins and Their Receptors as Modulators and Indicators of Alloimmune Responses. Am J Transplant (2016) 0.75
Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease. Ann Transl Med (2016) 0.75
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. J Clin Invest (2017) 0.75
The emerging role of sST2 blocking in the therapy of graft-versus-host disease. Ann Transl Med (2016) 0.75
Targeting Cytokines in GVHD Therapy. J Immunol Res Ther (2017) 0.75
Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation. Bone Marrow Transplant (2017) 0.75
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol (2017) 0.75
Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation. J Leukoc Biol (2017) 0.75
Predictive Value of Clinical Findings and Plasma Biomarkers after 14 Days of Prednisone Treatment for Acute Graft-Versus-Host Disease. Biol Blood Marrow Transplant (2017) 0.75
IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine (2017) 0.75
Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant (2017) 0.75
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Plasticity of CD4+ T cell lineage differentiation. Immunity (2009) 8.08
IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2006) 5.08
Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 4.92
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood (1996) 4.65
The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One (2008) 4.52
Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity (2009) 4.49
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest (2007) 4.31
The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE (2003) 4.14
T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med (2000) 3.76
T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A (1998) 3.61
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med (1998) 3.53
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol (2009) 3.41
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 3.39
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 3.11
The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature (2014) 3.10
IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol (2008) 3.09
IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A (2010) 3.07
Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol (2007) 2.99
IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 2.93
IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A (2009) 2.83
IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol (2008) 2.83
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation (2003) 2.62
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 2.52
IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol (2007) 2.43
Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol (2009) 2.42
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine (2007) 2.33
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A (2007) 2.27
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
The alarmin interleukin-33 drives protective antiviral CD8⁺ T cell responses. Science (2012) 2.10
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum (2009) 2.03
Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med (2001) 2.02
Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem (2009) 2.00
Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut (2012) 1.97
The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol (2009) 1.95
IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol (2009) 1.92
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood (2009) 1.80
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun (2009) 1.71
Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med (2012) 1.69
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood (2009) 1.67
Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest (2000) 1.65
Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.65
Target antigens determine graft-versus-host disease phenotype. J Immunol (2004) 1.57
STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease. Immunity (2012) 1.56
IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol (2009) 1.54
Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med (2001) 1.51
Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett (1993) 1.50
IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol (2012) 1.43
Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3⁺ regulatory T-cell responses in mice. Mol Med (2012) 1.37
Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun (2001) 1.36
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol (2010) 1.27
Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood (2008) 1.24
Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol (2012) 1.22
STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood (2008) 1.21
IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol (2011) 1.12
IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol (2011) 1.11
Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int (2011) 1.07
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood (2002) 0.98
Intraperitoneal influx of neutrophils in response to IL-33 is mast cell-dependent. Blood (2012) 0.96
IL-1 family members IL-18 and IL-33 upregulate the inflammatory potential of differentiated human Th1 and Th2 cultures. J Immunol (2012) 0.91
Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia (2012) 0.91
Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease. Biol Blood Marrow Transplant (2007) 0.91
Implications for Interleukin-33 in solid organ transplantation. Cytokine (2013) 0.89
Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun (1999) 0.88
IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol (2011) 0.86
Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells. Cell Mol Immunol (2012) 0.84
Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cell Immunol (2011) 0.84